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Abstract. 
PAR1 plays a central role in mediating the interplay between coagulation and inflammation, 
but its role in regulating acute neutrophilic inflammation is unknown. We report that 
antagonism of PAR1 was highly effective at reducing acute neutrophil accumulation in a 
mouse model of LPS-induced lung inflammation.  PAR1 antagonism also reduced alveolar-
capillary barrier disruption in these mice. This protection was associated with a reduction in 
the expression of the chemokines CCL2 and CCL7, but not the pro-inflammatory cytokines 
TNF and IL-6 or the classic neutrophil chemoattractants CXCL1 and CXCL2. Antibody 
neutralisation of CCL2 and CCL7 significantly reduced LPS-induced total leukocyte and 
neutrophil accumulation, recovered from the bronchoalveolar lavage fluid of challenged 
mice. Immunohistochemical analysis revealed CCL2 predominantly localised to alveolar 
macrophages and pulmonary epithelial cells, while CCL7 was restricted to the pulmonary 
epithelium. In keeping with these observations, the intranasal administration of rCCL2 and 
rCCL7 led to the accumulation of neutrophils within the lung airspaces of naïve mice in the 
absence of any underlying inflammation.  Flow cytometry analysis further demonstrated an 
increase in Ly6Ghi neutrophils expressing the chemokine receptors CCR1 and CCR2 isolated 
from mouse lungs compared to circulating neutrophils. Conversely, the expression of CXCR2 
decreased on neutrophils isolated from the lung compared to circulating neutrophils. 
Furthermore, this switch in chemokine receptor expression was accentuated following acute 
LPS-induced lung inflammation. Collectively, these findings reveal a novel role for PAR1 
and the chemokines CCL2 and CCL7 during the early events of acute neutrophilic 
inflammation. 
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Introduction 
The early stage of acute inflammation is usually associated with an influx of neutrophils into 
the injured tissue. Although this rapid innate immune response provides immediate host 
protection against infectious microorganisms, excessive leukocyte accumulation can lead to 
over-exuberant inflammation and tissue damage (1). Understanding the factors that control 
the early accumulation of neutrophils is critical in the context of both host defence and for the 
control of immunopathology associated with lung diseases such as acute respiratory distress 
syndrome (ARDS).  
 
The lung epithelium functions as a mucosal barrier that prevents the entry of noxious 
substances from the environment and performs the essential function of gaseous exchange. It 
is therefore vital that pulmonary epithelial integrity is maintained in order to sustain these 
essential physiological functions. If this barrier is compromised, a complex series of 
pathways are initiated, involving the interplay between inflammation and coagulation, which 
provides host defence against infection and promotes wound healing and the maintenance of 
the endothelial-epithelial barrier (2). This process is highly complex and involves many 
factors, including cytokines, chemokines, growth factors, cell adhesion molecules and 
coagulation proteins. 
 
Many of the cellular effects of coagulation proteinases are mediated via activation of the 
proteinase activated receptors (PARs), which are a family of G protein-coupled receptors 
(GPCRs) comprised of four members (PAR1-4). Evidence obtained from biochemical studies 
and from knockout mice suggests a key role for the major high-affinity thrombin receptor 
PAR1 in mediating the complex interplay between coagulation and inflammation in response 
to lung injury (2-5). It is known that PAR1 regulates vascular integrity to systemic 
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inflammation and modulates the release of pro-inflammatory cytokines (6). This may involve 
complex interactions between various proteinases such as thrombin and matrix 
metalloproteinases, as well as inflammatory mediators. Activation of PAR1 on epithelial 
cells, monocytes/macrophages and vascular endothelial cells leads to the release of pro-
inflammatory mediators, including the cytokines TNF, IL-1β, IL-2 and IL-6 and the 
chemokines CXCL8 (IL-8) and CCL2 (MCP-1) (2), mediators that have been directly 
associated with neutrophil activation, migration and the pathogenesis of ARDS (7, 8). Indeed, 
the alveolar-capillary barrier disruption associated with lung injury has been attributed to the 
immediate influx of neutrophils into the airspaces (9). 
 
Neutrophils are constantly trafficking through the pulmonary circulation and are rapidly 
recruited into the lung in response to multiple inflammatory mediators, of which the 
chemokine CXCL8 (IL-8), and the functional mouse homologues CXCL1 (KC) and CXCL2 
(MIP-2α), are considered the most potent chemoattractants for neutrophil extravasation 
across endothelial and epithelial surfaces (1). Elevated levels of CXCL8 have also been 
associated with several inflammatory diseases, including ARDS (10). However, the 
contribution of other chemokines to neutrophil recruitment to the lung is less clear, although 
several studies have recently implicated CCL2 in this process (11, 12). CCL2, and the related 
chemokine CCL7, are predominantly associated with the egress of monocytes out of the bone 
marrow in response to pro-inflammatory stimuli (13-15), and the recruitment of monocytes 
and macrophages into peripheral tissue during episodes of inflammation or infectious disease 
(16, 17). However, it is uncertain if these CC-chemokines contribute to the early migration of 
neutrophils, in response to direct lung injury, or whether the lung affords unconventional 
chemotactic properties on migrating neutrophils. 
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We now demonstrate that inhibiting PAR1 using a selective PAR1 antagonist dampens the 
accumulation of neutrophils into alveolar spaces and reduces alveolar leak following LPS-
induced inflammation. Furthermore, antagonism of PAR1 attenuated the expression of the CC 
chemokines, CCL2 and CCL7, rather than mediators classically associated with neutrophil 
migration. Importantly, neutrophil recruitment into inflamed lung airspaces was significantly 
decreased by antibody neutralization of CCL2 and CCL7, demonstrating that both these 
chemokines play a key role in the trafficking of neutrophils into the inflamed lung. 
Immunohistochemical analysis revealed that both CCL2 and CCL7 predominantly immuno-
localised to the pulmonary epithelium, although CCL2 also localised to the endothelium and 
alveolar macrophages. The instillation of recombinant CCL2 or CCL7 further confirmed a 
role for these chemokines in the recruitment of neutrophils into the lung. Moreover, CCL7 
had a preferential effect on neutrophil accumulation compared to CCL2. Indeed, neutrophils 
isolated from lung tissue were found to express the chemokine receptors CCR1, CCR2 and 
CCR3, while CCR1 and CCR2 expression was further enhanced during inflammation. Taken 
together, these findings have important implications for our understanding of the interaction 
between coagulation and CC-chemokines during acute neutrophilic inflammation. 
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Materials and Methods 
 
Pulmonary inflammation model. 
Experiments were conducted with local ethical approval in accordance with the Home Office, 
UK. Female BALB/c mice (6-8 weeks; Charles River, UK) were anaesthetised (5% 
isofluorane) and challenged with LPS in sterile saline (125 μg/kg, 50 μl i.n.; Escherichia coli 
0127:B8; Sigma, UK). Three hours later, animals were euthanised (urethane i.p. 20 g/kg), and 
bronchoalveolar lavage performed (3 × 0.5 ml to a total of 1.5 ml, PBS). Total and 
differential cell counts were quantified following cytospin. Alternatively, BAL fluid was 
isolated and whole lungs were removed and homogenized.  
 
Treatment protocols 
Mice were injected i.p with the specific PAR1 antagonist (αS)-N-[(1S)-3-amino-1-
[[(phenylmethyl)amino]carbonyl]propyl]-α-[[[[[1-(2,6-dichlorophenyl)methyl]-3-(1-
pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]amino]-3,4-
difluorobenzenepropanamide RWJ-58259 (5 mg/kg, a kind gift from Claudia Derian, Johnson 
and Johnson Pharmaceutical Research & Development, USA) 30 min after LPS 
administration. This antagonist is highly specific for PAR1 and does not interact with other 
PARs or GPCRs. Formulations were used as described previously (18, 19). The specificity, 
pharmacological characteristics and optimal dosing regimen have been previously described 
(19-21) and the biological properties of the compound recently reviewed (22). In other 
experiments, mice received 10 μg (i.n.) anti-CCL2 (R&D Systems), anti-CCL7 (Peprotech), 
anti-CXCL10 (R&D Systems) or anti-CX3CL1 (R&D Systems) specific neutralising 
antibodies at the same time as LPS i.n.. BAL fluid was analysed at 3 hours. Recombinant 
8 
 
rCCL2 or rCCL7 (both Peprotech) were administered to Balb/c mice (500 ng/mouse i.n) in 
sterile PBS. BAL fluid was analysed at 3 hours as described above. 
 
LDA PCR analysis 
Total RNA was extracted from pulverised frozen lung using TRIzol (see manufacturer’s 
protocol (Invitrogen)), DNase treated using a DNA free kit (Ambion) and cDNA synthesised 
from 1 μg RNA/per sample using a Superscript kit (Invitrogen). Expression levels of known 
inflammatory mediators were analysed in cDNA using Taqman low density array PCR chips 
and normalised to 18s. Relative differences in expression were calculated using the ΔCT 
method. 
 
MPO,chemokine and protease measurement 
Lung tissue homogenates were prepared as described previously (23). Briefly, frozen lung 
powder was mixed with PBS (10% w/v) containing protease inhibitors (Complete Mini; 
Roche Diagnostics, UK). Samples were homogenized on ice (Eppendorf), centrifuged 
(16,000g, 4°C, 15 min) and MPO  measured by ELISA (Hycult Biotechnology). Serum 
albumin levels were measured by ELISA (Bethyl Laboratories. Chemokine levels in 
supernatants were measured by Luminex. IFN-γ, CCL2, CCL7 and IL-8 were also measured 
by ELISA (Peprotech). Thrombin-anti-thrombin levels were measured by ELISA 
(EnzymeResearch). Activated protein C, matrix metalloproteinase-1, MMP-2 and ELA-2 
were also measured by ELISA (Antibodies Online). Receptor for advanced glycation 
endproducts (RAGE) was measured by ELISA (Abcam).  
 
Immunohistochemical detection of CCL2, CCL7 and PAR1  
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Briefly, mouse lungs were inflated with 4% formaldehyde, dehydrated through a aserila 
alcohol gradient and embedded in paraffin wax..  Serial sections (4 µm) were dewaxed and 
antigens unmasked by microwaving sections with 10 mM sodium citrate buffer (pH 6.0). 
Endogenous peroxide activity was blocked with 3% hydrogen peroxide and sections were 
blocked with 3% horse serum with 1% BSA in PBS for goat primary antibodies and with 3%  
goat serum with 1% BSA in  PBS for rabbit marker prior incubation with primary antibodies. 
Sections were incubated for 16 h at 4°C with primary antibodies; anti-CCL2 (0.4 µg/ml, 
Santa Cruz Biotechnology), anti-CCL7 (1 µg/ml PeproTech) and andy-PAR1 (2 µg/ml, Santa 
Cruz Biotechnology). Goat and Rabbit IgG controls (Vector Laboratories) were included as a 
negative control. Sections were incubated for 30 min with biotin labelled anti-goat or anti 
rabbit secondary antibodies (Vector Laboratories, UK),  followed by  30 min incubation with 
ABC complex (Vector Laboratories, UK).  Colour was developed with DAB chromogen 
(BioGenex)  for  5 min. Sections were counterstained with haemotoxylin , dehydrated and 
permanently mounted.  Slides were digitally scanned using a NanoZoomer (Hamamatsu) at 
the equivalent of ×200 magnification. 
 
Analysis of CCRs by flow cytometry. 
Blood was isolated in heparinised tubes from naïve and LPS challenged mice. Lung was 
isolated and homogenised as previously described. Both tissues underwent red blood cell 
lysis (Roche). Leukocytes were stained with anti-Ly6G-PE monoclonal antibody (BD 
Biosciences, clone IA8), anti-CCR1-FITC, anti-CCR2-APC and anti-CCR3-PerCP, or anti-
CXCR2-PerCP (all AbdSetotec). Neutrophils (Ly6Ghigh) were specifically gated on FSc-
Ly6Ghigh and the percentage of neutrophils expressing each chemokine receptor calculated. 
10 
 
Isotype and fluorescence minus one controls were used to set compensations and gating 
strategies. 
 
Statistical analysis.  
Statistical analysis was performed using Graphpad Prism software. Comparison of more than 
two groups was evaluated by Two Way ANOVA. Real time PCR data was analysed by the 
ΔCT method. Differences in cytokine or chemokine mRNA expression, protein release or cell 
number between treatment groups was evaluated by One Way ANOVA with Newman-Keuls 
method for post hoc pair wise comparisons,  by Mann-Whitney t-test or unpaired t-test with 
Welch’s correction. A p value of less than 0.05 was considered significant.  
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Results 
PAR1 signalling contributes to acute lung inflammation.  
In order to determine the role of PAR1 in the early stages of acute lung inflammation, we 
evaluated the effect of a potent and highly selective PAR1 antagonist (RWJ58259) following 
intranasal challenge with LPS (125 μg/kg). The PAR1 antagonist was administered (5 mg/kg 
RWJ58259, i.p.) 30 min after LPS challenge, the dose chosen on the basis of previous reports 
of effective in vivo PAR1 inhibition at this concentration (20, 21). As expected, LPS caused a 
significant increase in total cell and neutrophil recruitment into alveolar spaces after 3 h 
(Figure 1A and 1B), events that are indicative of the early stages of acute inflammation (24). 
Antagonism of PAR1 30 min after the onset of lung inflammation significantly decreased 
total cell and neutrophil numbers recruited to the airspaces (Figure 1A and 1B). Macrophage 
numbers in BAL fluid remained unchanged in all treatment groups, indicating that PAR1 
antagonism did not affect early macrophage recruitment (Figure 1C). The effect of PAR1 
antagonism on LPS-induced neutrophil recruitment was independently verified by flow 
cytometry, which demonstrated a decrease in Ly6G+ neutrophils recovered from BAL fluid 
and from whole lung homogenates (Figure 1D). Furthermore, PAR1 antagonism resulted in 
decreased myeloperoxidase (MPO) levels in lung homogenates (Figure 1E). In order to 
examine the effect of PAR1 antagonism on LPS-induced disruption of the alveolar-capillary 
barrier, serum albumin levels were measured in BAL fluid recovered from saline and LPS 
challenged mice. Serum albumin levels were increased in the BAL fluid of LPS challenged 
mice, and were significantly decreased (p=0.004) following PAR1 antagonism (Figure 1F). 
These data therefore demonstrate that PAR1 signalling influences early neutrophilic 
inflammation and promotes alveolar-capillary barrier disruption in a model of acute lung 
inflammation.  
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In order to assess the effect of PAR1 antagonism on the subsequent progression of 
neutrophilic inflammation, mice were challenged with LPS (125 μg/kg, i.n.) followed by 
RWJ58259 treatment 30 min thereafter. Mice were then euthanized at 6 h and 24 h after LPS 
challenge and the number of BAL fluid neutrophils assessed. A single dose of PAR1 
antagonist, given 30 min after LPS challenge, reduced neutrophil accumulation at 6 h and 24 
h (Figure S1). In order to determine the cellular and molecular mechanisms underlying this 
inflammatory process we focused on events occurring 3 h following LPS challenge. 
The pro-inflammatory effects of PAR1 signalling are mediated by the coagulation proteinase 
thrombin, while cytoprotective effects are mediated by activated protein C bound to its 
endothelial receptor EPCR (25). In order to determine the relative influence of thrombin 
versus APC following LPS-induced lung injury, we measured thrombin-anti-thrombin (TAT) 
complexes and APC in the BAL fluid and lung homogenates of control and LPS treated mice. 
A significant elevation of TAT was observed in the BAL fluid following LPS-challenge, but 
no increase in APC was observed (Figure S2). In order to rule out any effects of alternative 
proteinases on PAR1 activation, the matrix metalloproteinases MMP-1 and MMP-2, and 
neutrophil elastase (ELA2) were measured. No differences in the expression levels of any of 
these proteinases were detected following LPS-challenge (Figure S2). In addition, no 
difference in the levels of the receptor for advanced glycation endproducts (RAGE) was 
detected, suggesting that epithelial cell death does not contribute to the inflammatory 
response during the acute phase (Figure S2).  
 
PAR1 signalling influences the expression of multiple inflammatory mediators. 
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To investigate the mechanism by which PAR1 signalling influences acute lung inflammation, 
we next examined the effect of LPS challenge and subsequent PAR1 antagonism on pro-
inflammatory cytokine and neutrophil-specific chemokine levels in lung homogenates. In 
order to identify potential PAR1-regulated cytokines and chemokines, we used a low density 
rt-PCR array to enable the profiling of 91 inflammatory mediators (Table S1). Of the 91 
genes analysed, 31 genes were differentially expressed in lung tissue following challenge 
with LPS compared to saline treatment.  The differential gene expression profile included the 
upregulation of several genes known to be important for the generation of inflammatory 
responses, such as TNF, interleukins, CXC chemokines and CC chemokines. Further analysis 
revealed that 13 genes exhibited decreased expression following PAR1 antagonism (Table 
S1). However, PAR1 antagonism did not attenuate the expression of the conventional pro-
inflammatory cytokines TNF and IL-6 (Figure 2A and 2B), or the CXCR2 ligands CXCL1 
and CXCL2 (Figure 2C and 2D), suggesting that these cytokines/chemokines are not 
regulated downstream of PAR1 signalling in this model of LPS-induced lung inflammation.  
 
Of those genes upregulated following LPS challenge, PAR1 antagonist treatment decreased 
the expression of several CC and CXC chemokines, interleukins and TNF-related factors. 
Importantly, two closely related CC-chemokines CCL2 and CCL7 were decreased following 
treatment with the PAR1 antagonist (Figure 2E and 2F). These chemokines are known to 
induce the egress of monocytes from the bone marrow and recruit monocytes/macrophages 
into inflamed tissue (14, 15). However, these chemokines are not generally considered to be 
major chemoattractants for neutrophils. 
 
In order to confirm the LDA expression analysis, we measured protein levels in lung 
homogenates. Treatment with LPS significantly increased the expression of TNF, IL-6, 
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CXCL1 and CXCL2 (Figure 3A, 3B, 3C and 3D), but the expression of these proteins was 
not affected by PAR1 antagonist treatment. Similarly, LPS challenge increased the expression 
of CCL2 and CCL7 (Figure 3E and 3F) and, as observed in the LDA rt-PCR analysis, PAR1 
antagonist treatment also decreased the expression of these chemokines at the protein level. 
These data provide strong support to the notion that PAR1 plays a role in regulating CCL2 
and CCL7 expression following LPS-induced lung inflammation. 
 
CCL2 and CCL7 contribute to leukocyte accumulation following LPS challenge. 
In order to examine the potential roles of CCL2 and CCL7 in LPS-induced lung 
inflammation, we used specific neutralizing antibodies to block these chemokines. Treatment 
with the CCL2 or CCL7 neutralising antibodies reduced respective chemokines to basal 
levels at 3 h (Figure 4A and 4B), and therefore confirmed effective target engagement. 
Administration of anti-CCL2 antibody significantly decreased both the total cell number and 
the number of neutrophils isolated from BAL fluid following challenge with LPS (Figure 4C 
and 4D). Neutralisation of CCL2 also decreased the number of macrophages isolated from 
the BAL fluid after LPS challenge (Figure 4E). Administration of anti-CCL7 antibody also 
significantly reduced total cell and neutrophil accumulation into airspaces following LPS 
challenge (Figure 4F and 4G). However, neutralisation of CCL7 did not affect the number of 
macrophages (Figure 4H). Taken together, these data led us to conclude that both CCL2 and 
CCL7 influence early neutrophil accumulation into the inflamed lung, although only CCL2 
had a significant effect on the number of pulmonary macrophages. 
Since LDA PCR analysis indicated that the LPS induced chemokines CXCL10 and CX3CL1 
may be responsive to treatment with the PAR1 antagonist (Table S1), in vivo neutralization 
experiments were also performed with antibodies to CXCL10 or CX3CL1. No decrease in 
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neutrophil accumulation was observed following neutralisation of these chemokines (Figure 
S3), suggesting that these chemokines are not directly involved in neutrophil migration into 
the LPS-inflamed lung.   
 
CCL2, CCL7 and PAR1 immunolocalisation in inflamed lung. 
The observation that neutrophil migration downstream of PAR1 activation was mediated by 
the non-classical neutrophil chemokines, CCL2 and CCL7, was unexpected. In order to 
determine the cellular source of these chemokines we next examined the immunolocalisation 
of CCL2 and CCL7 in serial lung sections from saline treated and LPS-challenged mice. 
Weak CCL2 staining was detected in lung sections from saline treated animals (Figure 5A). 
However, following LPS treatment there was increased immunolocalisation of CCL2 in 
bronchial epithelial cells, alveolar macrophages, and endothelial cells, and to a lesser extent 
alveolar epithelial cells (Figure 5B and 5C). Similarly, there was weak CCL7 staining in 
saline treated control lung, which was mainly restricted to the bronchial epithelium (Figure 
5D), while CCL7 immunostaining of bronchial epithelial cells was markedly increased in 
response to LPS injury (Figure 5E and 5F). However, little immunolocalisation of CCL7 was 
detected in endothelial cells, alveolar epithelial cells or alveolar macrophages, suggesting that 
CCL2 and CCL7 are expressed within different lung microcompartments. 
Immunolocalisation of PAR1 demonstrated differential expression in lung microenvironments 
including the bronchial epithelium and alveolar macrophages in saline treated mouse lung 
(Figure 5G). An increase in PAR1 staining was detected in bronchial epithelial cells, alveolar 
macrophages and endothelial cells following LPS challenge (Figure 5H and 5I). 
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In order to gain an understanding of the relative contributions of PAR1 and LPS signalling on 
the release of CCL2 and CCL7, bronchial epithelial cells (Beas2Bs) and monocytes (THP-1) 
were stimulated with thrombin, LPS or a combination of the two. Thrombin and LPS induced 
the release of CCL2 from bronchial epithelial cells, while only LPS stimulated the release of 
CCL2 from THP-1 cells. Neither thrombin nor LPS stimulated the release of CCL7 from 
either bronchial epithelial or monocytic cell lines (Figure S4). In contrast, only thrombin 
stimulation induced the release of IL-8 from epithelial cells, while only LPS induced the 
expression of IL-8 in monocytes (Figure S4). Considering thrombin and LPS were unable to 
stimulate CCL7 release, while CCL7 immunolocalised to the pulmonary epithelium, we next 
tested the effects of the classical inflammatory mediators TNF, IFN-γ or a combination of 
TNF and IFN-γ (cytomix) on CCL2 and CCL7 release from epithelial cells. Both TNF and 
IFN-γ readily induced the release of CCL2 (Figure S5). In contrast, only a combination of 
TNF and IFN-γ stimulation caused a substantial release of CCL7, while IFN-γ alone induced 
the release of a small but significant amount of CCL7 (Figure S5). In order to assess the role 
of IFN-γ downstream of PAR1 in vivo, mice were challenged with LPS and treated with the 
PAR1 antagonist RWJ58259 30 min later. However, PAR1 antagonism had no effect on IFN-
γ expression in either BAL fluid or whole lung tissues. 
 
Neutrophils migrate into lung airspaces in response to CCL2 and CCL7. 
In order to determine the whether CCL2 and CCL7 are able to directly recruit leukocytes into 
the lung, we next administered recombinant CCL2 or CCL7 into the lungs of naïve mice and 
sampled the BAL fluid after 3 h. Direct instillation of either rCCL2 or rCCL7 increased the 
total cell number recovered from BAL fluid compared to saline treated controls (Figure 6A). 
The magnitude of the response was greater for rCCL2 compared to rCCL7. Differential cell 
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counts revealed that administration of rCCL2 or rCCL7 resulted in the recruitment of 
neutrophils into lung airspaces (Figure 6B). When expressed as a percentage of total cells 
recovered from BAL fluid, the data revealed that rCCL7 promoted a preferential 
accumulation of neutrophils compared to rCCL2 (Figure 6C), although total neutrophil 
numbers were similar. Furthermore, rCCL2 induced the recruitment of greater numbers of 
monocytes/macrophages into the BAL fluid compared to rCCL7 (Figure 6D and 6E). Taken 
together, these data reveal that CCL2 and CCL7 attract neutrophils into the lung in the 
absence of any underlying inflammation, and that CCL7 preferentially promotes the 
recruitment of neutrophils compared to CCL2, while CCL2 recruits both high levels of both 
macrophages and neutrophils. 
 
Neutrophils express CC-chemokine receptors in the inflamed lung. 
In order to assess the capacity of neutrophils to respond to CC-chemokines, we next assessed 
the expression of the known CC-chemokine receptors CCR1, CCR2 and CCR3 by 
neutrophils isolated from the blood and lungs of naïve and LPS-challenged mice, and 
compared the expression of these receptors with the major neutrophil chemoattractant 
receptor CXCR2, by flow cytometry. Minimal expression of CCR1, CCR2 or CCR3 was 
observed on neutrophils isolated from the blood of naïve and LPS challenged mice (Figure 
7A and 7B). In comparison, nearly all neutrophils isolated from the blood expressed CXCR2 
(Figure 7A and 7B). A small percentage of neutrophils isolated from naïve lung expressed 
CCR1, CCR2 and CCR3 (Figure 7C), compared to >95% of neutrophils that expressed 
CXCR2 (Figure 7C). Following LPS challenge the number of neutrophils expressing CCR1 
and CCR2 isolated from lung tissue increased (Figure 7D). The percentage of CCR2 
expressing neutrophils, in particular, increased from ~10% in naïve lung to greater than 35% 
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following LPS challenge (Figure 7D). There was no change in neutrophils expressing CCR3 
isolated from inflamed lung tissue compared to naïve lung (Figure 7D). Interestingly, 
concurrent with increased CCR1 and CCR2 expression, the percentage of CXCR2 expressing 
neutrophils decreased following challenge with LPS (Figure 7E). In a naïve lung >95% of 
neutrophils expressed CXCR2, while <60% of neutrophils expressed CXCR2 following LPS 
challenge, indicating that the chemokine receptor repertoire of neutrophils changes when 
migrating into lung tissue during an inflammatory response. 
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Discussion 
Neutrophil accumulation at sites of inflammation is essential for the early innate immune 
response to infection but is also associated with sterile inflammatory events. Although an 
influx of neutrophils is important for the control of infection and clearance of pathogens and 
damaged cells, excessive neutrophilia can lead to further tissue damage and 
immunopathology (26). In the context of lung injury, the potentially fatal lung condition 
ARDS is characterised by disruption of the alveolar-capillary interface, resulting in leakage 
of fluid into the interstitium and alveolar compartment, and the accumulation of neutrophils 
within airspaces (27). Current evidence suggests that excessive neutrophil accumulation 
contributes to tissue damage and alveolar-capillary barrier disruption (28), and is directly 
associated with the severity of disease (29-31). Furthermore, alveolar-capillary barrier 
disruption has been directly associated with the immediate influx of neutrophils (3 h), rather 
than peak of influx (24 h) or secondary events of neutrophil migration (9).  However, the 
endogenous factors and pathways that influence the rapid recruitment of neutrophils into the 
inflamed lung remain poorly defined. We now report that neutrophil recruitment into the lung 
airspaces is attenuated by antagonism of the high affinity thrombin receptor, PAR1, in a 
mouse model of LPS-induced lung inflammation.  
PAR1 antagonists have been investigated extensively as potential anti-platelet agents for the 
treatment of thrombotic diseases. For example, RWJ-58259 significantly reduced thrombus 
platelet aggregation in a cynomolgus monkey model of vascular injury-induced thrombosis, 
by specifically targeting PAR1 and not PAR2-4 (21). The same antagonist also attenuated 
vascular injury in a vascular restenosis model involving balloon angioplasty in rats (20). 
Importantly, our in vivo studies used a dose of RWJ-58259 that was consistent with these 
previous reports. It is now recognised that the vascular barrier-modulatory effects of the 
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PAR1 signalling axis are much more complex and are highly dependent on the nature and 
concentration of the activating proteinase. For example, at high concentrations, thrombin 
promotes endothelial cell contraction and vascular leak via activation of PAR1 in association 
with the sphingosine-1-phosphate receptor S1P3. In contrast, both low concentrations of 
thrombin and activated protein C (APC) mediate barrier protective effects by signalling via 
PAR1 in association with the endothelial protein C receptor (EPCR)  and S1P1 (25). PAR1 is 
now considered to be a receptor for danger signals, influencing the release of several pro-
inflammatory mediators. Our data suggest that thrombin is the key proteinase that activates 
PAR1 in this model of lung injury. Although other proteinases, such as MMP-1 and 
neutrophil elastase, can activate PAR1 under certain inflammatory conditions (6, 32) these 
proteinases are unchanged and therefore unlikely to play a major role during the acute phase 
of lung inflammation in our model. Furthermore, apoptotic signals and mediators released 
from damaged epithelial cells are also likely to modulate the inflammatory response and 
contribute to the complex signalling processes that occur during lung injury (32). 
Previous studies have demonstrated that PAR1 signalling can lead to the release of certain 
pro-inflammatory cytokines such as TNF, IL-6 and CXCL8 (IL-8) (33-36). In the present 
study we now show that PAR1 signalling influences the expression of CCL2 and CCL7, 
which in turn contribute to the accumulation of neutrophils into inflamed lung tissue. It is 
recognized that chemokines (particularly CXC chemokines) play a key role in regulating 
neutrophil migration into lung tissue (37, 38), and animal models of ARDS have been 
instrumental in revealing a central role for CXCL8 in neutrophil migration into the lung (1). 
There is compelling evidence that CXCL8, and the functional mouse homologues CXCL1 
and CXCL2, are released by alveolar macrophages and lung epithelial cells in response to 
key inflammatory mediators, such as LPS, TNF and IL-1β (39). Release of CXCL8 from 
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these cells establishes a chemokine gradient that not only provides neutrophils with 
directional movement but also delivers an activation signal that primes these cells during the 
process of trans-endothelial migration. Although it is clear that CXCL8 is important for the 
regulation of neutrophil migration (40), it is far from clear the extent to which other 
chemokines contribute to neutrophilic inflammation.  
Previous studies have shown that neutralisation of CXCL8 in the BAL fluid of patients with 
mild ARDS (acute lung injury) does not completely abolish the neutrophil chemotactic 
activity of this fluid (10), suggesting that other chemotactic factors are present that contribute 
to neutrophil migration. Indeed, several other chemokines have been implicated in neutrophil 
migration, including CXCL10 (IP-10) (41), CXCL5 (ENA-78) (42), and CCL2 (11, 12). 
Taken together, these observations suggest that although classical chemoattractants such as 
CXCL8 (or murine CXCL1 and CXCL2) likely play key roles, neutrophils are capable of 
responding to a variety of chemoattractants when migrating into inflamed tissue. However, 
the influence that individual chemokines have on neutrophil migration is likely to be 
dependent on the inflammatory stimulus and the tissue in which the chemokine is acting. In 
the case of the lung, we would reason that tissue-specific signals within unique 
microenvironments may be required for effective neutrophil migration across the pulmonary 
capillary endothelium and alveolar epithelium. 
In the present study, we now demonstrate that neutrophil migration into inflamed lung tissue 
following LPS challenge is mediated by CCL2 and CCL7. Indeed, we found that PAR1 
antagonism was not associated with a reduction in the expression of the classic murine 
neutrophil chemoattractants, CXCL1/CXCL2, following LPS-induced inflammation, but 
rather influenced CCL2 and CCL7 levels. The observation that PAR1 signalling contributes 
to CCL2 expression in the inflamed lung is consistent with our previous findings reported in 
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the context of fibrotic lung injury, where we demonstrated that PAR1 deficiency is associated 
with an attenuated CCL2 response in the mouse model of bleomycin-induced lung fibrosis 
(23, 36, 43).  We now show that PAR1 antagonism is also associated with a reduction in 
CCL2 and CCL7 levels, indicating that PAR1 signalling influences the expression of two CC 
chemokines not commonly recognised as classical neutrophil chemoattractants. Antibody 
neutralization studies further revealed that CCL2 and CCL7 contribute to neutrophil 
accumulation in LPS-induced acute lung inflammation. It is clear from previous findings (43) 
that CCL2 is directly regulated by PAR1 signalling. Immunohistochemical analysis of 
sections from mouse lungs challenged with LPS support this notion, as CCL2 and PAR1 co-
localised primarily to the bronchial epithelium, endothelium and alveolar macrophages. 
Furthermore, stimulation of bronchial epithelial cells in vitro with the PAR1 activating 
proteinase thrombin led to increased CCL2 production. However, compared to wide-spread 
immunostaining observed for CCL2, CCL7 immunoreactivity was primarily restricted to the 
bronchial epithelium, indicating that these two chemokines are differentially expressed within 
specific lung microcompartments. Furthermore, in our in vitro studies we were unable to 
demonstrate a direct functional link between PAR1 signalling and CCL7 release in either 
bronchial epithelial cells or monocytic cells, further supporting the notion that CCL2 and 
CCL7 are regulated by different signalling pathways. In contrast, a combination of TNF and 
IFN-γ was effective at inducing the release of CCL7, suggesting that CCL7 expression may 
require highly pro-inflammatory signals, the complexity of which is not easily mimicked in 
an in vitro setting. Direct instillation of rCCL2 and rCCL7 further showed that these 
chemokines alone can elicit neutrophil recruitment into naïve lungs. In particular, rCCL7 
preferentially promoted the recruitment of neutrophils compared to CCL2, although absolute 
numbers recovered from BAL fluid were similar. We propose that this effect may be 
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explained by the greater promiscuity of CCL7, which can bind several receptors including 
CCR1, CCR2 and CCR3, whereas CCL2 only signals through CCR2.  
CCL2 is widely regarded as a major monocyte chemoattractant, while CCL7 has previously 
been shown to act as a chemoattractant for several leukocyte populations including basophils, 
mast cells, eosinophils, DCs, T lymphocytes and monocytes/macrophages (44, 45). In 
particular, CCL7 has been shown to act as a monocyte chemoattractant during bone marrow 
egress in conjunction with CCL2, a process that is dependent on the expression of CCR2 
(15). However, the function of CCL2 and CCL7 remain poorly understood during leukocyte 
migration into peripheral tissue and may be critically dependent on the type of inflammatory 
stimulus and the site of injury (28, 46, 47).  
We now demonstrate that neutrophils migrating into the lung in response to LPS also 
upregulate CCR1 and CCR2. Conversely, CXCR2 expression was downregulated on 
neutrophils from inflamed lung. These studies highlight the potential of neutrophils to 
respond to CC-chemokines, which in turn may have important implications for the 
therapeutic inhibition of these receptors, and of CXCL8, in the control of neutrophilic 
inflammation. Studies that aim to further our understanding of neutrophil CC-chemokine 
receptor usage during lung inflammation are currently in progress; as it will be important to 
fully elucidate the dynamics of neutrophil recruitment with respect to the acquisition of novel 
chemokine receptors within different tissue microenvironments. 
In conclusion, we provide strong support that PAR1 signalling contributes to alveolar-
capillary barrier disruption and neutrophil accumulation following LPS-induced lung 
inflammation by influencing the levels of the CC-chemokines CCL2 and CCL7. Our findings 
further suggest that CCL2 and CCL7 are not only differentially regulated by disparate 
signalling pathways within specific lung microenvironments, but that they also differentially 
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influence the recruitment of inflammatory leukocytes, albeit with overlapping functional 
modalities. Achieving the appropriate balance of reducing excessive neutrophil accumulation 
without impacting host innate immune function represents a major challenge for the treatment 
of acute and chronic inflammatory conditions. Modulating this CC-chemokine response via 
antagonism of PAR1 signalling, or by blocking these chemokines directly, may represent 
novel opportunities for interfering with excessive neutrophilia and tissue damage in diseases 
such as ARDS and potentially other conditions associated with acute neutrophilic 
inflammation. In terms of strategies aimed at inhibiting PAR1 signalling, PAR1 antagonists 
are currently being evaluated as novel anti-thrombotic agents in several large multi-centre 
trials (48, 49). Our findings provide support for extending the evaluation of these agents in 
the context of ARDS and potentially other acute neutrophilic inflammatory conditions. 
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Figure Legends. 
 
Figure 1. PAR1 antagonist treatment significantly attenuates LPS induced lung injury. 
Mice were euthanized 3 hours after LPS (125 μg/kg i.n.) or saline challenge with or without 
the highly selective PAR1 antagonist RWJ-58259 (5 mg/kg) dosed therapeutically (i.p.) after 
30 min. Lungs were lavaged (1.5 ml PBS total) or removed and homogenised for FACS 
analysis. Total (A) and differential BAL fluid neutrophils (B) were quantified by 
haemocytometer and cytospin counts. BAL fluid macrophages were also differentially 
counted from cytospin preparations (E). Ly6G+ neutrophils (Ly6Ghigh F4/80low/neg) isolated 
from BAL fluid or lung homogenates were further assessed by flow cytometry (D). 
Neutrophil myeloperoxidase (MPO) activity in lung homogenates was assessed by ELISA 
(E). Alveolar-capillary barrier permeability was measured as serum albumin in BAL fluid by 
ELISA (F).  Panel shows mean values for at least n=5/group from three separate experiments.  
Data were analysed by one way ANOVA with Newman-Keuls Post Hoc test: ***p<0.0001, 
**p<0.01, *p<0.05. 
 
Figure 2. Low density array analysis of inflammatory markers following PAR1 
antagonism. Mice were euthanized 3 hours after LPS (125 μg/kg i.n.) or saline challenge 
with or without the the highly selective PAR1 antagonist RWJ-58259 (5 mg/kg) dosed 
therapeutically (i.p.) after 30 min. Lungs were removed, snap frozen and homogenised under 
liquid nitrogen before RNA was isolated and run on a low density gene array consisting of 
151 inflammatory markers (Supplementary table 1). Gene expression following LPS 
treatment revealed 25 markers that exhibited reduced expression following PAR1 antagonism. 
Of these genes the pro-inflammatory cytokines TNF (A) and IL-6 (B), and the neutrophil 
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chemoattractants CXCL1 (C) and CXCL2 (D) are depicted. In addition, the chemokines 
CCL2 (E) and CCL7 (F) were measured. Panel shows mean values for at least n=5/group 
from three separate experiments. Data were analysed by one way ANOVA with Newman-
Keuls Post Hoc test:, **p<0.01, *p<0.05. 
 
Figure 3. PAR1 antagonist treatment decreases CCL2 and CCL7 expression. Mice were 
euthanized three hours after LPS (125 μg/kg i.n.) or saline challenge with or without the 
PAR1 antagonist RWJ-58259 (5 mg/kg) dosed i.p. after 30 min. Lungs were removed and 
homogenized. Levels of TNF (A), IL-6 (B) CXCL1 (C), and CXCL2 (D) protein were 
measured in lung homogenates using a Luminex bead array. Protein levels of CCL2 (H) and 
CCL7 (I) were measured from lung homogenates by ELISA. Panel shows mean values for at 
least n=5/group from three separate experiments. Data were analysed by one way ANOVA 
with Newman-Keuls post hoc test: ***p<0.001, **p<0.01, *p<0.05. 
 
Figure 4. CC-chemokines influence early leukocyte accumulation in response to LPS 
challenge. Mice were euthanized three hours after LPS (125 μg/kg i.n.) or saline challenge. 
Mice were administered with anti-CCL2 or anti-CCL7 neutralising antibody (10 μg/mouse), 
or control IgG, within the nasal challenge volume. Lungs were removed, homogenised and 
CCL2 (A) and CCL7 (B) levels measured by ELISA following anti-CCL2 or anti-CCL7 
antibody treatment. Lungs were lavaged and BAL fluid total cells (C), neutrophils (D) and 
macrophages (E) quantified following administration of anti-CCL2. Following anti-CCL7 
treatment lungs were lavaged and BAL fluid total cells (F), neutrophils (G) and macrophages 
(H) quantified. Mean and sem values of at least n=5 per group for 2 separate experiments are 
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shown for each treatment. Data were analysed by one way ANOVA with Newman-Keuls 
post hoc test: **p<0.01, *p<0.05; n.s. not significant. 
Figure 5. Immunohistochemical analysis of CCL2, CCL7 and PAR1 expression in the 
lungs of LPS-treated mice. Mice were euthanized three hours after LPS (125 μg/kg i.n.) or 
saline challenge. Lungs were inflated with 4% formaldehyde and serial paraffin embedded 
sections (4 µm) cut. Immunohistichemistry was performed on each section to detect CCL2 
(A, B and C), CCL7 (D, E and F) or PAR1 (G, H and I). Images were digitally captured using 
a NanoZoomer (Hamamatsu) at the equivalent of ×200 magnification. High magnification 
images were taken of LPS-treated lungs equivalent to ×400 magnification (C, F and I). 
Images are representative of 5 mice per treatment group. 
 
Figure 6. CCL2 and CCL7 induce an influx of leukocytes into the BAL fluid. Naïve mice 
were administered with either rCCL2 or rCCL7 (500 ng/mouse, i.n.) and 3 h later BAL fluid 
was recovered. BAL fluid total cell counts (A) were measured following rCCL2 and rCCL7 
treatment. Differential cell counts were performed on isolated BALF by cytospin. The total 
number of neutrophils (B) and the percentage of neutrophils (C) in BAL fluid were 
calculated. In addition, the total number of macrophages (D) and the percentage of 
macrophages (E) in BAL fluid were calculated. Data were analysed by one way ANOVA 
with Newman-Keuls post hoc test: *p<0.05, **p<0.01,*** p<0.001. 
 
Figure 7. CC-chemokine receptor expression of neutrophils isolated from the blood and 
lung. Mice were administered with LPS (125 μg/kg i.n.) or without (naïve) and blood and 
lungs isolated and single cell suspensions prepared. Cells were stained for Ly6G and the 
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neutrophil population specifically gated (Ly6Ghigh against FSc). The expression of CCR1, 
CCR2, CCR3 and CXCR2 on neutrophils was calculated and represented as dot plots. 
Neutrophils isolated from naïve blood (A), LPS treated blood (B), naïve lungs (C) and LPS-
treated lungs (D) were analysed and the percentage of chemokine receptor positive cells 
calculated (E). Data are representative of 5 mice per group. Data were analysed by one way 
ANOVA with Newman-Keuls post hoc test: *p<0.05 compared to naïve blood. 
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Figure 7. 
 
 
Supplementary Figure Legends. 
 
Fig. S1. PAR1 antagonism moderates airspace neutrophilia after 6 and 24 h. Mice were 
euthanized 6 h or 24 h after LPS (125 μg/kg i.n.) or saline challenge with and without the 
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PAR1 antagonist RWJ-58259 (5 mg/kg) dosed therapeutically (i.p) after 30 min. Lungs were 
lavaged (1.5 ml PBS total) and the neutrophils counts after 6 h (A) and 24 h (B). Data were 
analysed by one way ANOVA with Neuman-Keuls Post Hoc test: *p<0.05. 
 
Fig. S2. Elevated levels of thrombin-anti-thrombin (TAT) complex in inflamed 
airspaces. Mice were euthanized 3 h after LPS (125 μg/kg i.n.) or saline challenge. BAL 
fluid was isolated and the levels of TAT (A) and APC (B) measured. Whole lung tissue was 
homogenised and the levels of TAT (C), APC (D), MMP1 (E), MMP2 (F), neutrophil 
elastase (ELA2) (G) and receptor for advanced glycation end products (RAGE) (H) measured 
by ELISA. 
 
 
Fig. S3. Neutralisation of CXCL10 and CX3CR1 did not result in a decrease in airspace 
neutrophilia. Mice were euthanized three hours after LPS (125 μg/kg i.n.) challenge with or 
without PAR1 antagonist. LDA analysis of CXCL10 (A) and CX3CL1 (B) mRNA levels 
(normalised to 18s housekeeping gene). Mice were administered CXCL10 or CX3CL1 
neutralising antibody (10 μg/mouse) within the LPS nasal challenge volume. Lungs were 
lavaged (1.5 ml PBS total) and differential BAL fluid neutrophils quantified following 
administration of anti-CXCL10 (C) or anti-CX3CL1 (D) neutralising antibodies. Data were 
analysed by one way ANOVA with Neuman Keuls post hoc test. **p<0.01. 
 
Fig. S4. The expression of CCL2, CCL7 and IL-8 is differentially induced by thrombin 
and LPS. The bronchial epithelial cell line Beas2B and the macrophage cell line THP-1 were 
stimulated with thrombin (10 nM), LPS (100 ng/ml) or a combination of the two. The levels 
of CCL2 expressed by epithelial cells (A) or macrophages (B) were measured by ELISA. 
Similarly, the levels of CCL7 expressed by epithelial cells (C) or macrophages (D) were 
46 
 
measured by ELISA. IL-8 levels were also measured following stimulation of epithelial cells 
(E) and macrophages (F). Data were analysed by unpaired t-test with Welch’s correction 
(*p<0.05 compared to media control). 
 
Fig. S5. CCL7 is expressed in response to TNF and IFN-γ. The bronchial epithelial cell 
line Beas2B was stimulated with TNF (20 ng/ml), IFN-γ (20 ng/ml) or a combination of both. 
CCL2 (A) and CCL7 (B) levels were measured by ELISA. Data were analysed by unpaired t-
test with Welch’s correction (*p<0.05 compared to media control). In separate experiments 
mice were euthanized 3 h after LPS (125 μg/kg i.n.) or saline challenge. The expression of 
IFN-γ in isolated BAL fluid (C) and whole lung homogenates (D) was measured by ELISA. 
Data were analysed by unpaired t-test with Welch’s correction (*p=0.03) 
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Suplementary Table S1. Low density PCR array raw data. 
 
Challenge/ Treatment 
Gene Saline/ Vehicle LPS/ Vehicle 
 
LPS/ RWJ58259   
  Mean sem Mean sem 
LPS/ Veh 
vs  
Sal/ Veh 
(p-value) Mean sem 
LPS/ RWJ  
vs  
Sal/ Veh 
(p value) 
LPS/ Veh 
vs  
LPS/ RWJ       
(p value) 
Ccl 2 1.49 0.52 62.51 10.63 <0.0001 26.70 2.52 <0.0001 <0.05 
Ccl 3 1.12 0.29 41.03 9.13 <0.0001 31.86 1.98 <0.0001 ns 
Ccl 4 1.04 0.15 55.02 7.37 <0.0001 50.40 2.71 <0.0001 ns 
Ccl 7 1.11 0.20 28.19 6.14 <0.0001 9.33 1.34 <0.0001 <0.01 
Ccl 11 1.02 0.11 5.65 0.92 <0.0001 4.53 0.31 <0.0001 ns 
Ccl 17 1.11 0.25 16.18 2.64 <0.0001 18.59 1.86 <0.0001 ns 
Ccl 22 1.04 0.14 28.90 6.85 <0.0001 18.39 1.63 <0.0001 ns 
Cxcl 1 1.10 0.27 21.09 1.36 <0.0001 23.68 2.84 <0.0001 ns 
Cxcl 2 1.44 0.62 46.46 5.18 <0.0001 61.90 4.45 <0.0001 ns 
Cxcl 10 1.07 0.18 279.23 62.16 <0.0001 149.68 14.79 <0.0001 <0.05 
Cxcl 13 1.05 0.16 5.49 0.89 <0.0001 5.00 0.82 <0.0001 ns 
Cx3cl 1 1.01 0.07 3.15 0.62 <0.0001 1.42 0.07 <0.05 <0.0001 
Ccr 1 1.04 0.15 6.62 1.10 <0.0001 5.54 0.75 <0.0001 ns 
Ccr 3 1.06 0.19 0.83 0.20   0.28 0.04     
Ccr 4 1.20 0.34 2.92 0.75 <0.05 1.21 0.12 ns <0.05 
Ccr 7 1.03 0.14 1.29 0.22   0.93 0.11     
Ccr 8 1.21 0.42 1.82 0.48   2.16 0.48     
CXCR 2  1.08 0.21 13.42 2.52 <0.0001 12.53 1.49 <0.0001 ns 
Cxcr 3 1.07 0.21 0.60 0.05   0.58 0.08     
CXCR 5  1.04 0.15 0.92 0.18 ns 0.48 0.04 <0.05 <0.05 
Cxcr 6 1.38 0.38 2.00 0.51   1.17 0.21     
Bmp7 1.02 0.10 0.64 0.06 <0.01 0.51 0.07 <0.01 ns 
Col1a1 1.04 0.13 0.72 0.11 ns 0.47 0.03 <0.01 <0.05 
Csf2 1.11 0.28 18.25 1.87 <0.0001 14.00 2.63 <0.0001 ns 
Csf3 2.55 1.12 81.97 17.57 <0.0001 133.70 9.08 <0.0001 ns 
Ctgf 1.04 0.16 0.61 0.10 <0.05 0.54 0.07 <0.05 ns 
Ddr1 2.02 0.92 4.37 1.78   4.23 0.84     
Egf 3.81 1.69 6.39 1.00   2.67 0.89     
Egfr 1.07 0.17 1.47 0.33   1.48 0.17     
Ereg 1.11 0.28 6.24 1.09 <0.0001 9.84 0.86 <0.0001 ns 
Fbn1 1.02 0.09 0.96 0.18   0.84 0.08     
Fgf2 1.05 0.15 0.97 0.22   0.72 0.09     
Foxp3 1.02 0.09 1.94 0.35   1.25 0.40     
Gapd 1.01 0.08 0.80 0.12   0.80 0.11     
Hsp70 1.00 0.04 1.06 0.07   1.00 0.08     
Ifng 2.92 1.31 5.09 4.66   2.65 1.03     
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Il10 7.03 4.93 5.23 4.82   2.52 1.09     
Il10ra 1.02 0.11 2.33 0.39 <0.0001 1.39 0.12 ns <0.05 
Il10rb 1.01 0.06 1.61 0.19   1.44 0.14     
Il11 1.86 0.99 0.34 0.13   0.43 0.14     
Il12a 2.36 0.73 2.44 0.30   1.51 0.36     
Il12rb1 1.09 0.22 1.65 0.30   1.27 0.27     
Il12rb2 1.03 0.13 1.24 0.32   1.44 0.26     
Il13ra1 1.02 0.10 2.47 0.46   2.29 0.34     
Il13ra2 2.44 1.32 39.83 6.65 <0.0001 38.39 10.38 <0.0001 ns 
Il16 1.01 0.06 0.96 0.08   0.93 0.10     
Il18 1.04 0.14 1.20 0.15   1.12 0.13     
Il1a 1.04 0.15 2.53 0.20 <0.0001 1.99 0.10 <0.0001 ns 
Il1b 1.17 0.36 22.24 3.59 <0.0001 18.57 2.41 <0.0001 ns 
Il1r1 1.03 0.13 1.55 0.22   1.71 0.21     
Il1r2 1.11 0.23 20.13 5.05 <0.0001 38.28 4.76 <0.0001 <0.05 
Il2ra 1.23 0.37 2.21 0.40   2.26 0.14   ns 
Il5 3.08 1.72 8.90 4.00   5.35 1.51     
Il6 1.09 0.22 27.82 6.28 <0.0001 28.18 2.68 <0.0001 ns 
Il6ra 1.08 0.23 0.82 0.10   0.93 0.12     
Il7 1.04 0.13 0.65 0.08   0.55 0.09     
Mmp2 1.03 0.13 0.88 0.18   0.92 0.08     
Mmp3 1.05 0.16 1.74 0.27 <0.05 2.28 0.30 <0.01 ns 
Mmp9 1.19 0.26 6.83 0.99 <0.0001 6.71 0.70 <0.0001 ns 
Muc1 1.01 0.06 1.21 0.05   1.11 0.07     
Muc2 1.01 0.09 3.21 0.83   2.58 0.80     
Muc5b 1.05 0.15 0.99 0.23   0.96 0.11     
Pcoln3 1.04 0.13 1.31 0.16   1.36 0.15     
Pdgfb 1.01 0.05 0.93 0.05   0.69 0.04     
Pdgfb 1.01 0.09 1.08 0.12 ns 0.77 0.05 <0.05 <0.05 
Pdgfc 1.05 0.16 0.75 0.04 ns 0.62 0.06 ns <0.05 
Pdgfd 1.01 0.06 1.13 0.14   1.03 0.13     
Pdgfrb 1.04 0.13 0.96 0.20   0.90 0.08     
Rab3b 1.10 0.26 0.78 0.18   0.98 0.24     
Retn 1.17 0.31 1.54 0.12   1.53 0.27     
Retnla 1.11 0.28 1.11 0.15   1.36 0.13     
Retnlg 1.07 0.18 11.32 1.47 <0.0001 22.73 2.57 <0.0001 <0.01 
Serpinh1 1.02 0.10 1.09 0.14   0.61 0.08     
Sftpa 1.01 0.08 1.09 0.11   1.11 0.08     
Sftpb 1.01 0.09 0.78 0.05   0.89 0.06     
Sftpc 1.00 0.05 1.03 0.05   1.39 0.26     
Sftpd 1.02 0.10 2.17 0.20 <0.0001 2.43 0.23 <0.0001 ns 
Tgfb1 1.01 0.05 1.24 0.19   0.97 0.07     
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Tgfb1 1.01 0.07 1.35 0.29   1.06 0.12     
TGFbr1 1.05 0.18 0.92 0.13   0.74 0.09     
Tgfbr2 1.02 0.10 0.91 0.22   0.73 0.08     
Tlr2 1.06 0.18 6.08 1.26 <0.0001 5.20 0.54 <0.0001 ns 
Tlr3 1.05 0.15 2.37 0.47 <0.01 1.97 0.20 <0.05 ns 
Tlr4 1.03 0.13 1.07 0.24   0.92 0.10     
Tlr9 1.02 0.09 1.64 0.32   1.07 0.12     
Tnc 1.01 0.07 1.17 0.23 ns 0.67 0.06 <0.05 <0.05 
Tnf 1.10 0.25 14.34 2.44 <0.0001 14.15 0.94 <0.0001 ns 
Txnrd1 1.06 0.19 1.94 0.39   1.84 0.25     
Vamp8 1.01 0.06 1.65 0.05   1.67 0.10     
Vegfa 1.03 0.12 0.80 0.12   0.65 0.07     
Vim 1.01 0.08 0.78 0.15   0.65 0.07     
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Supplementary Figure 1. 
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Supplementary Figure 2. 
 
 
 
Supplementary Figure 3. 
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Supplementary Methods. 
In vitro cell culture. 
The bronchial epithelial cell line Beas2B or the macrophage cell line THP-1 were cultured in DMEM 
(Gibco) containing 10% fetal calf serum (Lonza), L-glutamine, penicillin and streptomycin (all 
Invitrogen). Prior to stimulation cells were washed twice with PBS and serum starved for 2 h in 
DMEM without 10% FCS. Cells were stimulated with 10 nM thrombin (Sigma), 100 ng/ml LPS 
(Sigma) or a combination of both. Alternatively, cells were stimulated with 20 ng/ml TNF 
(Invitrogen), 20 ng/ml IFN-γ (Invitrogen) or a combination of both. Supernatant was removed after 3 
h and CCL2, CCL7 and IL-8 were measured by ELISA (Peprotech). 
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Supplementary Figure 4. 
 
 
 
 
